NL-OMON28081RecruitingNot Applicable
Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma
Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC Cancer Institute, Clinical Trial CenterP.O. Box 20403000 CA RotterdamTel: 010 4391568Fax: 010 4391028e-mail: hdc@erasmusmc.nl0 sites260 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 260
Study Overview
Brief Summary
ot yet for this trial.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •First diagnosis of high risk Burkitt lymphoma (sporadic and
- •HIV associated), histologically confirmed according to the
- •WHO classification 2008. Upon its availability the WHO 2016
- •classification should be used, to replace the WHO 2008
- •classification;
Exclusion Criteria
- •- All histopathological diagnoses other than Burkitt
- •lymphoma according to the WHO classification 2008,
- •irrespective of the presence of a MYC rearrangement. Upon
- •its availability the WHO 2016 classification should be used, to
- •replace the WHO 2008 classification;
Investigators
Similar Trials
Active, not recruiting
Phase 1
Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphomaEUCTR2013-004394-27-BEHOVON Foundation260
Recruiting
Phase 3
Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphomaNL-OMON53047HOVO90
Active, not recruiting
Phase 1
A clinical study comparing two different chemotherapy options for patients with newly diagnosed Burkitt lymphomaHigh-risk Burkitt lymphomaMedDRA version: 20.0Level: LLTClassification code 10006605Term: Burkitt's tumor or lymphomaSystem Organ Class: 100000004864EUCTR2013-004394-27-GBHOVON Foundation260
Active, not recruiting
Phase 1
Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphomaHigh risk Burkitt LymphomaMedDRA version: 20.0 Level: LLT Classification code 10006605 Term: Burkitt's tumor or lymphoma System Organ Class: 100000004864EUCTR2013-004394-27-NLHOVON Foundation260
Completed
Phase 2
Phase II study of R-CODOX-M/R-IVAC therapy for the patients with newly diagnosed primary mediastinal large B-cell lymphomaPrimary mediastinal large B-cell lymphomaJPRN-UMIN000003793ational Cancer Center Hospital35